S&P 500   4,567.53 (+0.50%)
DOW   35,746.23 (+0.19%)
QQQ   378.30 (+1.12%)
AAPL   148.74 (+0.03%)
MSFT   308.76 (-0.13%)
FB   326.09 (+0.46%)
GOOGL   2,746.94 (-0.16%)
TSLA   1,019.48 (+12.07%)
AMZN   3,329.48 (-0.18%)
NVDA   233.25 (+2.64%)
BABA   176.00 (-0.96%)
NIO   41.19 (+5.94%)
CGC   13.44 (+0.45%)
GE   105.64 (+1.53%)
AMD   123.08 (+2.72%)
MU   68.95 (+2.13%)
T   25.46 (-0.12%)
F   15.96 (-1.97%)
ACB   7.16 (+1.27%)
DIS   172.23 (+1.66%)
PFE   43.03 (-0.30%)
BA   212.19 (-0.37%)
AMC   36.97 (+1.01%)
S&P 500   4,567.53 (+0.50%)
DOW   35,746.23 (+0.19%)
QQQ   378.30 (+1.12%)
AAPL   148.74 (+0.03%)
MSFT   308.76 (-0.13%)
FB   326.09 (+0.46%)
GOOGL   2,746.94 (-0.16%)
TSLA   1,019.48 (+12.07%)
AMZN   3,329.48 (-0.18%)
NVDA   233.25 (+2.64%)
BABA   176.00 (-0.96%)
NIO   41.19 (+5.94%)
CGC   13.44 (+0.45%)
GE   105.64 (+1.53%)
AMD   123.08 (+2.72%)
MU   68.95 (+2.13%)
T   25.46 (-0.12%)
F   15.96 (-1.97%)
ACB   7.16 (+1.27%)
DIS   172.23 (+1.66%)
PFE   43.03 (-0.30%)
BA   212.19 (-0.37%)
AMC   36.97 (+1.01%)
S&P 500   4,567.53 (+0.50%)
DOW   35,746.23 (+0.19%)
QQQ   378.30 (+1.12%)
AAPL   148.74 (+0.03%)
MSFT   308.76 (-0.13%)
FB   326.09 (+0.46%)
GOOGL   2,746.94 (-0.16%)
TSLA   1,019.48 (+12.07%)
AMZN   3,329.48 (-0.18%)
NVDA   233.25 (+2.64%)
BABA   176.00 (-0.96%)
NIO   41.19 (+5.94%)
CGC   13.44 (+0.45%)
GE   105.64 (+1.53%)
AMD   123.08 (+2.72%)
MU   68.95 (+2.13%)
T   25.46 (-0.12%)
F   15.96 (-1.97%)
ACB   7.16 (+1.27%)
DIS   172.23 (+1.66%)
PFE   43.03 (-0.30%)
BA   212.19 (-0.37%)
AMC   36.97 (+1.01%)
S&P 500   4,567.53 (+0.50%)
DOW   35,746.23 (+0.19%)
QQQ   378.30 (+1.12%)
AAPL   148.74 (+0.03%)
MSFT   308.76 (-0.13%)
FB   326.09 (+0.46%)
GOOGL   2,746.94 (-0.16%)
TSLA   1,019.48 (+12.07%)
AMZN   3,329.48 (-0.18%)
NVDA   233.25 (+2.64%)
BABA   176.00 (-0.96%)
NIO   41.19 (+5.94%)
CGC   13.44 (+0.45%)
GE   105.64 (+1.53%)
AMD   123.08 (+2.72%)
MU   68.95 (+2.13%)
T   25.46 (-0.12%)
F   15.96 (-1.97%)
ACB   7.16 (+1.27%)
DIS   172.23 (+1.66%)
PFE   43.03 (-0.30%)
BA   212.19 (-0.37%)
AMC   36.97 (+1.01%)
NASDAQ:XENT

Intersect ENT Stock Forecast, Price & News

$26.94
0.00 (0.00 %)
(As of 10/25/2021 02:55 PM ET)
Add
Compare
Today's Range
$26.82
$27.24
50-Day Range
$27.06
$28.01
52-Week Range
$14.68
$28.17
Volume4,392 shs
Average Volume405,651 shs
Market Capitalization$900.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
30 days | 90 days | 365 days | Advanced Chart
Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.


Intersect ENT logo

About Intersect ENT

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENT
Employees
406
Year Founded
N/A

Sales & Book Value

Annual Sales
$80.55 million
Book Value
$2.05 per share

Profitability

Net Income
$-72.32 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$900.33 million
Next Earnings Date
11/1/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

1002nd out of 1,360 stocks

Surgical & Medical Instruments Industry

100th out of 124 stocks

Analyst Opinion: 1.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT
or view top-rated stocks.

What stocks does MarketBeat like better than Intersect ENT?

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Intersect ENT
.

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings data on Friday, August, 6th. The medical equipment provider reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.07. The medical equipment provider earned $27.30 million during the quarter, compared to analyst estimates of $27.77 million. Intersect ENT had a negative trailing twelve-month return on equity of 102.23% and a negative net margin of 66.55%. Intersect ENT's revenue was up 178.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.65) earnings per share.
View Intersect ENT's earnings history
.

How has Intersect ENT's stock price been impacted by Coronavirus?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 25.3% and is now trading at $26.94.
View which stocks have been most impacted by COVID-19
.

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $117 million-$121 million, compared to the consensus revenue estimate of $119.79 million.

What price target have analysts set for XENT?

5 Wall Street analysts have issued 12-month price targets for Intersect ENT's shares. Their forecasts range from $23.00 to $32.00. On average, they expect Intersect ENT's share price to reach $27.96 in the next year. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Intersect ENT
or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Thomas A. West, President, Chief Executive Officer & Director
  • Randy Meier, Chief Financial Officer & Executive Vice President
  • Patrick A. Broderick, Secretary, Executive VP & General Counsel
  • Mark L. Alley, Vice President-Sales
  • Reyna M. Fernandez, Chief Human Resource Officer

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by many different retail and institutional investors. Top institutional investors include Havens Advisors LLC (0.27%), Strs Ohio (0.10%) and Sphinx Trading LP (0.02%). Company insiders that own Intersect ENT stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends for Intersect ENT
.

Which institutional investors are buying Intersect ENT stock?

XENT stock was bought by a variety of institutional investors in the last quarter, including Havens Advisors LLC, Strs Ohio, and Sphinx Trading LP. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT
or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $26.94.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $900.33 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72.32 million in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 406 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100 or via email at [email protected].


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.